ArticleAngewandte Chemie (International ed. in English)2026
Acinetobacter baumannii α2-6-Legionaminyltransferase-Catalyzed Synthesis Reveals Legionaminic Acid Form Selectivity by Antibodies in Pooled Human IgGs.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Legionaminic acids (Legs) are prokaryote-specific nine-carbon acidic monosaccharides belonging to the nonulosonic acid (NulO) family. Various Leg forms are found in the polysaccharides or glycoproteins produced by numerous pathogenic bacteria, including capsular polysaccharides of carbapenem-resistant Acinetobacter baumannii. Hypothetic legionaminyltransferases have been predicted from gene sequences but none has been biochemically validated. In this study we report the first biochemical characterization of a legionaminyltransferase. We demonstrate that AbGtr18 from an A. baumannii K8 strain is a donor promiscuous α2-6-legionaminyltransferase selective for α-N-acetylgalactosamine-glycoside (GalNAcαOR) acceptors. In addition, streamlined chemical synthetic routes, including regio-selective triflylation and azide substitution processes, were developed to prepare precursors or chemoenzymatic synthons of various forms of Legs. Applying the novel α2-6-legionaminyltransferase AbGtr18 in one-pot multienzyme (OPME) synthesis with or without additional chemical derivatization enabled rapid construction of a focused library of NulO-glycosides (NulOα2-6GalNAcαOR) containing nine NulO forms. Binding and inhibition studies with these compounds revealed selective Leg forms recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurrence of these Leg forms and indicating their prior encounters by human immune systems. AbGtr18 thus emerges as both a potential target for antibiotic development and a powerful biocatalyst for accessing synthetically challenging NulO-glycosides with therapeutical potentials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.